One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

FDA approves first once-monthly buprenorphine injection - picture 1

FDA approves first once-monthly buprenorphine injection

6 December 2017, 11:52 contact@life4me.plus

The US Food and Drug Administration (FDA) announced it has approved Sublocade, a once-monthly buprenorphine injection for moderate to severe opioid use disorder (OUD).

Current buprenorphine-based treatments for OUD employ an oral mode of administration and require daily intake, thus posing the issue of medication adherence. These treatments are also available in the form of an implant (Probuphine), which provides stable delivery of low-dose buprenorphine over a 6-month period.

The agency's commissioner, Scott Gottlieb, MD, noted the importance of providing an array of treatment options for OUD. "Everyone who seeks treatment for opioid use disorder deserves the opportunity to be offered the treatment best suited to the needs of each individual patient, in combination with counseling and psychosocial support, as part of a comprehensive recovery plan," he said.

Sublocade (RBP-6000) allows the sustained delivery of buprenorphine over a 1-month period, thanks to the Atrigel Delivery System, which, on subcutaneous injection, forms a solid deposit, subsequently broken down to steadily release the drug.

In a study investigating the efficacy of RBP-6000 the treatment was found to reduce "drug-liking" and demonstrated the safety and tolerability of the treatment for patients ages 17 to 65 years. Clinical studies showed that patients treated with Sublocade had fewer weeks with positive urine tests and self-reported opioid use vs patients receiving placebo.


Latest News

All news - picture 2

Chemsex is associated with an increased risk of HIV transmission and sexual infections

The use of gay, bisexual and other men who have sex with men (#MSM), crystallized methamphetamine, mephedrone, γ-hydroxybutyrate or γ-butyrolactone, and to a lesser extent cocaine and ketamine during sexual intercourse, or the so-called " the phenomenon is relatively new, ...

23 May 15:48

All news - picture 3

ART drug Juluca appears in European pharmacies

Pharmaceutical company ViiV Healthcare, specializing in the development and production of medicines for HIV treatment, reported that the European Commission issued a permit for the implementation in Europe of the combined drug Juluca (#dolutegravir 50 mg / rilpivirine 25 ...

22 May 14:30

All news - picture 4

Truvada in the US will be used to reduce the risk of HIV transmission among adolescents

Gilead Sciences, Inc. announced that the FDA approved once-daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Truvada) in combination with safe sex practices, to reduce the risk of sexually acquired HIV-1 in at-risk adolescents.

17 May 15:01

All news - picture 5

A patient has died from AIDS in Switzerland because he was not paid for HIV treatment

As it became known to the media, an HIV-positive patient died from AIDS in Switzerland in the end of 2017. He was being refused of a medical treatment due to missing necessary health insurance, and the insurance company refused several times to pay for the treatment because ...

1 May 14:29